DMC Cash Dividend 25% for 2025; Abbott Unit to Receive VND 45B

Overview

Domesco (DMC) has announced a 25% cash dividend for 2025, with a record date of September 15, 2025, and payment scheduled for October 21, 2026. The company’s parent, Abbott Laboratories (Chile) Holdco Spa, a subsidiary of Abbott Laboratories, will receive approximately VND 45 billion from the payout. The announcement comes alongside robust first-half 2026 results, with net profit up 39% year-on-year.

Key Facts

• DMC will pay a cash dividend of 25% (VND 2,500 per share) for fiscal year 2025.
• Record date: September 15, 2025; ex-right date: September 14, 2025; payment date: October 21, 2026.
• Total dividend payout estimated at VND 87 billion based on over 34.7 million shares outstanding.
• Abbott Laboratories (Chile) Holdco Spa, owning 51.69% of DMC, will receive about VND 45 billion.
• SCIC, the second-largest shareholder with 34.71%, will receive over VND 30 billion.
• H1 2026 revenue reached VND 1,039 billion, up 6% year-on-year; net profit after tax was nearly VND 110 billion, up 39%.
• DMC shares traded around VND 58,000 on August 23, 2026, down about 3% from the start of the year.

What Happened

Domesco (DMC) announced a cash dividend of 25% for 2025, equivalent to VND 2,500 per share. The record date is set for September 15, 2025, with the ex-right date on September 14, 2025, and payment expected on October 21, 2026. The company has over 34.7 million shares outstanding, leading to an estimated total payout of VND 87 billion.

Abbott Laboratories (Chile) Holdco Spa, a member of Abbott Laboratories and DMC’s parent with a 51.69% stake, will receive approximately VND 45 billion in dividends. The second-largest shareholder, SCIC (State Capital Investment Corporation), holding 34.71%, will receive over VND 30 billion. The company also reported strong first-half 2026 results, with revenue of VND 1,039 billion and net profit after tax of nearly VND 110 billion, representing increases of 6% and 39% year-on-year, respectively.

Market Context

DMC shares are trading around VND 58,000 on the HOSE, down about 3% since the start of 2026. The dividend yield at this price is approximately 4.31%. The pharmaceutical sector in Vietnam has been resilient, and DMC’s improved profitability reflects operational efficiencies and product mix optimization. The company’s strong H1 performance and dividend announcement may attract income-focused investors, though the stock’s year-to-date decline suggests broader market or sector-specific headwinds.

Strategic Significance

For long-term investors, DMC’s dividend declaration underscores its commitment to shareholder returns, supported by a solid balance sheet and improving earnings. The company’s focus on product portfolio review, sales policy optimization, and cost management has driven a 39% net profit increase, indicating effective execution. The presence of Abbott as a strategic parent provides governance and potential operational synergies. However, the payment date in late 2026 is unusually far out, which may reflect cash flow planning or regulatory requirements. Investors should monitor whether the company can sustain this payout level amid potential market volatility and input cost pressures.

What to Watch

• Q3 2026 earnings release to see if profit growth momentum continues.
• Any updates on the dividend payment timeline or changes in shareholder structure.
• Regulatory approvals or policy changes affecting the pharmaceutical sector.
• Movement in DMC’s share price relative to its dividend yield and sector peers.
• Abbott’s strategic initiatives for its Vietnamese operations, which could impact DMC’s growth trajectory.